VISCERAL ADIPOSITY
September 12, 2021ADIPOCYTE DIFFERENTIATION
September 12, 2021- SGLT inhibitors in management of diabetes
- Structural selectivity of human SGLT inhibitors
- A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized …
- SGLT inhibitors as antidiabetic agents: a comprehensive review
- International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors
- SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
- SGLT inhibitors for type 1 diabetes: proceed with extreme caution
- SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery
- Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol
- SGLT inhibitors for type 1 diabetes: an obvious choice or too good to be true?
- The anti-inflammatory effects of SGLT inhibitors
- Na+-Glucose Cotransporter (SGLT) inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4′-Dehydroxyphlorizin Derivatives Substituted …
- SGLT inhibitors as new therapeutic tools in the treatment of diabetes
- natural products as lead compounds for sodium glucose cotransporter (SGLT) inhibitors
- SGLT inhibitors for people with type 1 diabetes
- SGLT inhibitors: a novel target for diabetes
- Impact of SGLT inhibitors on Multiple Organ Defects in Diabetes.
- Effects of sodium‐glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: a meta …
- Pyrazole-O-glucosides as novel Na+-glucose cotransporter (SGLT) inhibitors
- Synthesis of isotopically labelled SGLT inhibitors and their metabolites
- Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense
- A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of SGLT inhibitors
- QSAR studies on triazole derivatives as SGLT inhibitors via CoMFA and CoMSIA
- Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?
- The bark giving diabetes therapy some bite: the SGLT inhibitors
- Effect of SGLT inhibitors on weight and lipid metabolism at 24 weeks of treatment in patients with diabetes mellitus: A systematic review and network meta …
- Synthesis of L-rhamnose derived chiral bicyclic triazoles as novel sodium-glucose transporter (SGLT) inhibitors
- SGLT inhibitors and euglycaemic diabetic ketoacidosis: earlier observations rediscovered
- Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis‐the STOP DKA protocol
- Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1, 2, 3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors
- SGLT inhibitors for type 1 diabetes
- Factors that predict glycaemic response to sodium‐glucose linked transporter (SGLT) inhibitors
- The bark giving diabetes therapy some bite: the SGLT inhibitors
- SGLT inhibitors attenuate NO‐dependent vascular relaxation in mouse pulmonary artery (677.3)
- SGLT inhibitors for type 1 diabetes: a finely balanced matter?
- Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
- Novel SGLT inhibitors (SGL5083 and SGL5085), Acting on Both Suppressing Intestinal Glucose Absorption and Increasing Urinary Glucose Excretion, Improve …
- SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
- SGLT inhibitors Enhance Endogenous Glucose Productions (EGP) in a Preclinical Animal Model
- SAT-662 Effects of SGLT inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis
- Correction: Synthesis of l-rhamnose derived chiral bicyclic triazoles as novel sodium-glucose transporter (SGLT) inhibitors
- Sodium-glucose co-transporter (SGLT) inhibitors: a novel class of oral anti-diabetic drugs
- Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1, 2, 3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors
- Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
- Sodium–glucose cotransporter–2 (SGLT-2) inhibitors and the treatment of type 2 diabetes
- Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk
- … -2 inhibitors and cardiovascular protection: lessons and gaps in understanding the current outcome trials and possible benefits of combining SGLT-2 inhibitors …
- The effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors on cardiometabolic profile; beyond the hypoglycaemic action
- Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT‐2 inhibitors and GLP‐1 receptor agonists
- The Effects of DPP-4 inhibitors, GLP-1RAs, and SGLT-2/1 inhibitors on heart failure outcomes in diabetic patients with and without heart failure history …
- SGLT-2 inhibitors-hope or hype?-an updated review
- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and …
- The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 inhibitors and Pioglitazone
- PDB29 A COST-UTILITY ANALYSIS OF SODIUM-GLUCOSE COTRANSPORTER (SGLT) 2 inhibitors IN ADDITION TO BASAL-BOLUS INSULIN IN THE …
- Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic …
- Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
- Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting
- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for cardiovascular disease prevention
- Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin
- Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis
- A novel SGLT-2 score to identify HFpEF patients who may benefit from SGLT-2 inhibitors
- Recent Advances on SGLT 2 inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events
- Possible sodium-glucose cotransporter-2 (SGLT-2) inhibitors for reducing effects of blood glucose and also blood pressure
- Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational …
- SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control
- Update on Cardiovascular Benefits with Sodium Glucose Cotransporter-2 inhibitors (SGLT-2i). On J Cardio Res & Rep. 1 (5): 2019
- Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors
- Sodium–glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class
- Sodium-glucose cotransporter Type 2 (SGLT-2) inhibitors and ketogenesis: The Good and the Bad
- A Case Report of Euglycemic Diabetic Ketoacidosis in the Setting of Keto Diet and SGLT-2 inhibitors
- Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors and cancer: a meta‐analysis of randomized controlled trials
- 2232: Acute kidney injury in patients on SGLT-2 inhibitors: A propensity matched analysis
- Short and medium‐term efficacy of sodium glucose co‐transporter‐2 (SGLT‐2) inhibitors: A meta‐analysis of randomized clinical trials
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
- 480: COMPARISON OF TREATMENT OF KETOACIDOSIS ASSOCIATED WITH SGLT-2 inhibitors AND USUAL DKA
- Novel oral hypoglycemic agents SGLT-2 inhibitors: cardiovascular benefits and potential mechanisms
- Management of type 2 diabetes mellitus with overweight: Focus on SGLT-2 inhibitors and GLP-1 receptor agonists
- Can sodium glucose cotransporter 2 (SGLT-2) inhibitors be beneficial in patients with acute myocardial infarction?
- … Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis
- The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes
- Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested …
- Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials
- Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce hospitalization for heart failure only and have no effect on atherosclerotic cardiovascular events …
- SGLT-2 inhibitors and peripheral artery disease: a statistical hoax or reality?
- Use of Sodium–Glucose Cotransporter 2 (SGLT-2) inhibitors Beyond Diabetes: On the Verge of a Paradigm Shift?
- An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
- Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
- SGLT-2 inhibitors: a new mechanism for glycemic control
- Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors)
- SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
- In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
- SAT-685 Euglycemic Diabetic Ketoacidosis in T1d: The Era of SGLT-2 inhibitors and Keto-Diet
- SGLT‐2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects
- The kidney as a new target for antidiabetic drugs: SGLT 2 inhibitors
- Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta …
- Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment
- Dynamics of epicardiac fat and heart function in type 2 diabetic patients initiated with SGLT-2 inhibitors
- The safety of dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors added to metformin background therapy in patients with …
- Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience
- Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
- Diabetic ketoacidosis in patients with type 2 diabetes recently commenced on SGLT-2 inhibitors: an ongoing concern
- 194 SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes
- Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes
- SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists
- GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients
- Off-label prescription of SGLT-2 inhibitors to patients with type 1 diabetes: an online survey of diabetes specialists in Italy
- The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease
- SGLT 2 inhibitors; glycemic control, weight loss and safety profile in patients with type 2 Diabetes, at Medicell Institute (MIDEM)
- Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials
- The role of SGLT-2 inhibitors in the treatment of type 2 diabetes
- SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials
- Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
- Noninvasive monitoring of liver fat during treatment with GLP‐1 analogues and SGLT‐2 inhibitors in a real‐world setting
- Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study.
- Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide
- SGLT-2 inhibitors and GLP-1 agonists: first-line therapy for diabetes with established cardiovascular disease
- The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes
- A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy …
- GLP-1 Agonists and SGLT-2 inhibitors in Type 2 Diabetes Patients
- Short-and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis
- MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 inhibitors-an Under-recognized Diagnosis
- … and biological evaluation of (2S, 3R, 4R, 5S, 6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3, 4-diols as potent and orally active SGLT dual inhibitors
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus …
- Does gender influence the cardiovascular benefits observed with sodium glucose co-transporter-2 (SGLT-2) inhibitors? A meta-regression analysis
- Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes
- Rates of myocardial infarction and stroke in patients initiating treatment with SGLT 2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: R …
- … agents in type 1 diabetes in addition to insulin therapy: metformin, alpha-glucosidase inhibitors, pioglitazone, GLP-1 agonists, DPP-IV inhibitors, and SGLT-2 inhibitors
- Efficacy and Safety of SGLT-2 inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis
- SGLT-2 inhibitors: is there a role in type 1 diabetes mellitus management?
- Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence
- SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL
- How do SGLT-2 inhibitors work to prevent heart failure?
- SGLT-2 inhibitors as adjunctive to insulin therapy in type 1 diabetes
- SGLT 2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature
- Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a …
- Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 inhibitors
- 4111 Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis
- SGLT-2 inhibitors in heart failure: implications for the kidneys
- SGLT-2 inhibitors and their potential in the treatment of diabetes
- Emerging role of SGLT-2 inhibitors for the treatment of obesity
- SGLT 2 inhibitors act from the extracellular surface of the cell membrane
- Safe and pragmatic use of sodium-glucose co-transporter 2 (SGLT 2) inhibitors: medication counseling
- SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
- SAFETY ISSUES WITH THE USE OF SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT-2) inhibitors
- Re: diabetic ketoacidosis in patients with type 2 diabetes on SGLT-2 inhibitors: an ongoing concern
- SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies
- SGLT‐2 inhibitors and the risk of lower‐limb amputation: is this a class effect?
- … Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) inhibitors
- SGLT-2 inhibitors: potential novel strategy to prevent congestive heart failure in diabetes?
- Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials
- Structure–Activity Relationship Study of Acyclic Terpenes in Blood Glucose Levels: Potential α-Glucosidase and Sodium Glucose Cotransporter (SGLT-1) inhibitors
- Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors: Benefits in Diabetics With Cardiovascular Disease
- Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation
- SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
- A look to the future in non-alcoholic fatty liver disease: Are GLP-1 analogues or SGLT-2 inhibitors the answer?
- Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 1 diabetes
- P2519 Comparison of SGLT-2 inhibitors, GLP-1 agonist and DPP-4 inhibitors for mortality outcomes in participants with type 2 diabetes: a network meta-analysis of 96 …
- Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors
- Effects of GLP-1 Receptor Agonists and SGLT-2 inhibitors in Heart Transplant Patients with Type 2 Diabetes: a Case Series
- Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
- The beneficial hemodynamic actions of SGLT-2 inhibitors beyond the management of hyperglycemia
- Sodium–glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead
- Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints
- Class effect for SGLT-2 inhibitors: a tale of 9 drugs
- Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence
- Do the SGLT-2 inhibitors offer more than hypoglycemic activity?
- Adverse effects and safety of SGLT-2 inhibitors
- New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors
- 66 Acute coronary syndrome in type 2 diabetes treated using SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors: a comparative network meta-analysis of …
- Long-term effectiveness and safety of SGLT-2 inhibitors in an Italian cohort of patients with type 2 diabetes mellitus
- Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart …
- Sodium Glucose Co-Transporter 2 (SGLT-2) inhibitors: A Review
- Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive …
- 1233-P: Systematic Literature Review (SLR) and Network Meta-analysis (NMA) of SGLT-1/2 inhibitors vs. Metformin (MET) as Add-On to Insulin in T1DM
- 301P Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for alpelisib (ALP)-induced hyperglycemia: A report of 6 cases from SOLAR-1
- Comparison in Methods Between National Institute for Health And Care Excellence (Nice) Submissions For Sodium-Glucose Co-Transporter 2 inhibitors (SGLT-2i …
- The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for …
- Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic …
- SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
- SGLT-2 inhibitors for COVID-19—A miracle waiting to happen or just another beat around the bush?
- Early initiation of sodium‐glucose linked transporter inhibitors (SGLT‐2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients
- SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives
- Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies
- Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis
- An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
- SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis
- Association Between Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors and Lower Extremity Amputation: A Retrospective Cohort Study
- Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
- SGLT-2 inhibitors in heart failure and type-2 diabetes: hitting two birds with one stone?
- SGLT-2 inhibitors: a novel mechanism in targeting glycemic control in type 2 diabetes mellitus
- Are SGLT-2 inhibitors the future of heart failure treatment? The EMPEROR-Preserved and EMPEROR-Reduced trials
- The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio-and nephroprotection
- SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
- Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and abdominal obesity: an Asian perspective and expert recommendations
- Elements for Success in Managing Type 2 Diabetes With SGLT-2 inhibitors: Role of the Kidney in Glucose Homeostasis: Implications for SGLT-2 Inhibition in the …
- The role of SGLT-2 inhibitors as part of optimal medical therapy in improving cardiovascular outcomes in patients with diabetes and coronary artery disease
- Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process
- SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin
- Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?
- SGLT-2 inhibitors and cardiovascular risk in diabetes mellitus: a comprehensive and critical review of the literature
- Liraglutide versus SGLT-2 inhibitors in people with type 2 diabetes: a network meta-analysis
- SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?
- SGLT-2 inhibitors: their pleiotropic properties
- Diabetes Consultations™: Beyond Insulin: The Role of SGLT-2 inhibitors in Care of Patients with T1DM
- In patients with uncontrolled type 2 diabetes, are GLP-1 agonists more effective than SGLT-2 inhibitors in lowering HbA1c?
- Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis
- The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
- Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC–MS/MS
- CHARACTERISTICS OF PATIENTS INITIATING SODIUM GLUCOSE COTRANSPORTER-2 inhibitors (SGLT-2I) COMPARED TO PATIENTS INITIATING OTHER …
- SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
- Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio …
- SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
- SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort
- SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
- SGLT-2 inhibitors and DPP-4 inhibitors as second-line drugs in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
- Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes
- Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: a systematic review and meta-analysis of cardiovascular …
- Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney …
- Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic …
- Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists
- Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes …
- Let’s Be More Sensitive—How SGLT-2 inhibitors and GLP-1 Receptor Agonists Affect β-Cell Function in Type 2 Diabetes: Comment on “Improved Beta Cell Glucose …
- Letter by Tampaki et al Regarding Article,“Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 inhibitors”
- Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized …
- Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
- Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials
- SGLT-2 inhibitors in diabetes: a focus on renoprotection
- Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational …
- The placebo response of injectable GLP‐1 receptor agonists vs. oral DPP‐4 inhibitors and SGLT‐2 inhibitors: a systematic review and meta‐analysis
- Mechanisms for Cardiorenal Protection of SGLT-2 inhibitors
- Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus
- SGLT-2 inhibitors in development for type 2 diabetes treatment
- SGLT-2 inhibitors in type 1 diabetes mellitus: a comprehensive review of the literature
- Cardiovascular effects of SGLT‐2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand
- Response to letter:’Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for SGLT-2 inhibitors?’
- Efficacy in metabolic control and weight loss of combined treatment with GLP-1 receptor analogues and SGLT-2 inhibitors
- SGLT-2 inhibitors in heart failure: A new therapeutic avenue
- Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management
- SGLT-2 inhibitors to treat hyponatremia associated with SIADH: a novel indication?
- Do SGLT‐2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
- Differentiating Among the SGLT-2 inhibitors: Considering Cardiovascular and Other Safety Outcomes
- … -transporter 2 inhibitors and serum uric acid: Re: Mende CW. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors …
- Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
- Sodium-Glucose Co-Transporter-2 (SGLT-2) inhibitors And The Risk of Fractures of The Upper or Lower Limb In Patients With Type 2 Diabetes: A Nested-Case …
- Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin
- Antidiabetic SGLT-2 inhibitors prevent progression of chronic kidney disease
- The use of SGLT-2 inhibitors in type 2 diabetes and heart failure
- Hospitalization for Heart Failure and Death in New Users of SGLT-2 inhibitors in Patients With and Without Cardiovascular Disease—CVD Real Study
- A Role for SGLT-2 inhibitors in Treating Non-diabetic Chronic Kidney Disease
- Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials
- The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: a European expert recommendation
- Sodium‐glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the …
- Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview
- Limitations of natriuretic peptide levels in establishing SGLT-2 inhibitors for heart failure care
- Prevention of cardiac allograft vasculopathy–A new possible indication for SGLT-2 inhibitors?
- SGLT-2 inhibitors as cardioprotective agents in COVID-19
- Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 inhibitors and GLP-1 Analogs?
- SGLT-2 inhibitors Use in Renal Transplant Patients with Diabetes: A Brief Review of the Current Literature.
- Lower Risk of Cardiovascular Events and Death Associated with Initiation of SGLT-2 inhibitors versus Other Glucose Lowering Drugs-Real World Data Across …
- SGLT-2 inhibitors Beneficial Effects on Ventricular Repolarization May Be Protective against Atrial Fibrillation Occurrence
- SGLT-2 inhibitors and regenerative cell exhaustion
- Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 inhibitors.
- SGLT-2 inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives
- The effect of SGLT‐2 inhibitors on mortality and heart failure in randomized trials versus observational studies
- … Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 inhibitors (SGLT …
- Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 …
- SGLT‐2 inhibitors and the risk of hospitalization for community‐acquired pneumonia: A population‐based cohort study
- SGLT-2 inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus.
- Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a …
- Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes
- SGLT‐2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization’s adverse drug reactions database
- Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice
- Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery
- Effects of cardiovascular function of SGLT-2 inhibitos versus DPP-4 inhibitors in type 2 diabetes with coronary artery disease
- Can SGLT-2 inhibitors resolve the heart failure burden of diabetes mellitus-Is it empaglifozin or the class?
- SGLT-2 inhibitors in diabetic kidney disease: what lies behind their renoprotective properties?
- Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials
- Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials
- … THE DIFFERENCES EFFECTS OF GLUCAGON LIKE PEPTIDE-1 (GLP-1) ANALOGUES AND SODIUM-COTRANSPORTER 2 (SGLT-2) inhibitors ON TYPE 2 …
- Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease …
- Effect of SGLT-2 inhibitors on non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus: Systematic review with meta-analysis and trial …
- A study of the effects of SGLT-2 inhibitors on diabetic cardiomyopathy through miR-30d/KLF9/VEGFA pathway
- SGLT-2 inhibitors in Heart Failure: Volume or Value?
- SGLT-2 inhibitors users profile recruited through a pharmacy-based intensive monitoring study: analysis of the pharmacotherapeutic profile, drug-drug interactions …
- The role of SGLT-2 inhibitors in managing type 2 diabetes.
- Use of SGLT-2 inhibitors in Patients With Type 1 Diabetes Mellitus
- In Reply to ‘Do SGLT-2 inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?’
- Postoperative euglycemic diabetic ketoacidosis and encephalopathy related to SGLT-2 inhibitors: a case report and discussion of diabetes treatment and “sweet pee …
- Trends in SGLT-2 inhibitors Usage in Heart Failure Patients With Type 2 Diabetes Mellitus, in a South-East Queensland Hospital
- SGLT-2 inhibitors for people with type 2 diabetes–Authors’ reply
- … and patient-centred outcome measures in randomized controlled trials conducted for diabetes pharmacotherapy: SGLT-2 receptor inhibitors as an example
- Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril–valsartan: does money matter?
- SGLT-2 inhibitors: are they a promising treatment option in T2DM patients with NAFLD?
- Do SGLT-2 inhibitors reduce albuminuria in people with diabetes?
- Renal Effects of SGLT‐2 inhibitors and Other Anti‐diabetic Drugs: Clinical Relevance and Potential Risks
- Ketogenic Diets, Ketoacidosis and SGLT-2 inhibitors-Part 2..
- Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction
- MON-602 The Efficacy and Safety of Sodium-Glucose Transport Protein 2 (SGLT-2) inhibitors for Weight Loss Among Individuals Without Diabetes: A Systematic …
- … Risk of Death and Cardiovascular Events in Unselected Type 2 Diabetes Patients Initiated on GLP-1 Receptor Agonists and SGLT-2 inhibitors in Two Large …
- SGLT-2 inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
- Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process
- … Reporting and Data System Category 3 (Equivocal) Lesions Identified Infection and Inflammation of the Genitourinary Tract Re: SGLT-2 inhibitors and the Risk of …
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus …
- Falls and SGLT-2 inhibitors in geriatric patients—A case report
- The Effect of SGLT-2 inhibitors and GLP-1 Agonists on Cardiovascular Disease in Patients with Type 2 Diabetes
- Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: a review protocol
- A Comprehensive Review on Analytical Method Development and Validation for SGLT-2 inhibitors by HPLC in Its API and Dosage Form
- Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 inhibitors
- Euglycemic Diabetic Ketoacidosis, SGLT-2 inhibitors and COVID-19; The Murphy Law of COVID-19
- Development of Efficient Routes to Access C-Glycosides as SGLT-2 inhibitors for the Treatment of Type 2 Diabetes
- Current Utilization Trends of SGLT-2 inhibitors in Type 2 Diabetics With Heart Failure
- SGLT-2 inhibitors for people with type 2 diabetes
- The placebo response of injectable GLP‐1 receptor agonists vs. oral DPP‐4 inhibitors and SGLT‐2 inhibitors: a systematic review and meta‐analysis
- SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
- SGLT-2 inhibitors: a novelty in the treatment of type 2 diabetes
- P2482 Sex-based differences in cardioprotective role of SGLT-2 inhibitors in patients with type 2 diabetes mellitus
- Correlations Between SGLT-2 inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs
- Expect the Unexpected: SGLT-2 inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure
- Analysis of Adverse Drug Reactions Induced by SGLT-2 inhibitors
- SGLT-2 inhibitors in heart failure: An updated systematic review and meta-analysis of 13 randomized clinical trials including 14618 patients with heart failure.
- SGLT-2 inhibitors DEMONSTRATE CONSISTENT REDUCTION IN CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALIZATIONS AN UP-TO …
- Overview of the efficacy and safety of SGLT-2 inhibitors in type 2 diabetes mellitus
- The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
- Glycosuria with SGLT-2 inhibitors–a new treatment approach for type 2 diabetes mellitus
- SGLT-2 inhibitors and circulating progenitor cells in diabetes
- Improving Glucose Control in Type II Diabetes with SGLT-2 inhibitors and GLP-1 Agonists
- Do SGLT-2 inhibitors improve cardiovascular outcomes in patients with type 2 diabetes?
- SGLT-2 inhibitors for people with type 2 diabetes
- Kidney Outcomes With SGLT-2 inhibitors
- SGLT-2 inhibitors and nephroprotection: a systematic review and meta-analysis
- SGLT-2 inhibitors-are they to stay?
- SGLT-2 inhibitors as adjunct therapy in type 1 diabetes: reason for hope and caution
- The method of reporting hypoglycemia in randomized control trials (RCTs): a systematic review on RCTs conducted for SGLT-2 inhibitors
- SGLT-2 inhibitors: The glucosuric antidiabetics
- SYSTEMATIC REVIEW OF COST-EFFECTIVENESS OF SGLT-2 inhibitors IN TYPE 2 DIABETES MELLITUS
- SGLT-2-inhibitors in Heart Failure
- SGLT 2 inhibitors: a new therapeutic target and its role in current clinical practice
- Renoprotective effect of SGLT-2 inhibitors vs ACE inhibitors in type 2 diabetes (presentation)
- Renoprotective effect of SGLT-2 inhibitors vs ACE inhibitors in type 2 diabetes
- FO042 EFFECT OF SGLT-2 inhibitors ON AMBULATORY BLOOD PRESSURE: DOSE-RESPONSE META-ANALYSIS AND COMPARATIVE EVALUATION WITH …
- Need of the hour: pharmacovigilance study of SGLT-2 inhibitors
- PDB13-SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF SGLT-2 inhibitors AND METFORMIN AS ADD-ON TO INSULIN FOR THE …
- Diabetes Management and Cardiovascular Risk: Are SGLT-2 inhibitors the Safest?
- The effect of SGLT-2 inhibitors on albuminuria and proteinuria in Diabetes Mellitus: a systematic review and meta–analysis of randomized controlled trials
- Falls and SGLT-2 inhibitors in geriatric patients—A
- SGLT 2 inhibitors improve cardiorenal outcomes in DM2–get rid of the sugar
- A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on metabolic parameters in patients with polycystic ovary syndrome (PCOS …
- MON-LB029 The Influence of SGLT-2 inhibitors and Other Glucose-Lowering Therapies on All-Cause Mortality Risk and Cardiovascular Outcomes in Older Patients …
- KETOACIDOSIS GENERATED BY TREATMENT WITH SGLT-2 inhibitors–A CASE REPORT
- Victoza®(liraglutide) provides greater glycaemic control than SGLT-2 inhibitors
- A Meta-Analysis of the Effects of SGLT-2 inhibitors on Serum Electrolytes
- Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials
- REAL WORLD SAFETY AND EFFICACY OF SGLT-2 inhibitors IN ELDERLY TYPE 2 DIABETIC PATIENTS
- The Influence of SGLT-2 inhibitors and Other Glucose-Lowering Therapies on Mortality Risk in Elderly Patients with Type 2 Diabetes
- Comparison of the effects of SGLT 2 inhibitors and sulfonylurea on electrocardiographic parameters
- Prescribing patterns of SGLT-2 inhibitors and GLP-1 agonist in patients with both DM and ASCVD
- SGLT-2 inhibitors
- TREATMENT WITH SGLT-2 inhibitors IN PATIENTS WITH DIABETES MELLITUS AND ESSENTIAL HYPERTENSION–DYNAMIC OF BLOOD PRESSURE VISIT-TO …
- Use of SGLT-2 inhibitors in Patients with Chronic Kidney Disease.
- Effect of SGLT-2 inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta …
- Effects of SGLT-2 inhibitors and Visceral Fat on Glucose Metabolism
- SGLT-2 inhibitors and amputation: A real or an overestimated risk?
- SGLT-2 inhibitors: a new therapy for diabetes
- SGLT-2 inhibitors as adjunctive therapy in type 1 diabetes: Short experience from a center
- SGLT-2 inhibitors: An Evidence-Based Perspective
- Advances in cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists
- A Multivariate Safety and Efficacy Analysis of Prescribing Information for Next Generation SGLT-2 inhibitors in Type 2 Diabetes Treatment
- SGLT-2 inhibitors in type 2 diabetes-protecting the kidney (and heart) beyond glucose control
- WHAT PHYSICIANS NEED TO KNOW ABOUT SGLT-2 inhibitors
- Cerebrovascular Complications of Diabetes: SGLT-2 inhibitors as a Promising Future Therapeutics.
- SGLT-2 inhibitors–aT The LimiTS
- Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
- SGLT inhibitor adjunct therapy in type 1 diabetes
- Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin
- Sodium-glucose co-transporter (SGLT) inhibitor restores lost axonal varicosities of the myenteric plexus in a mouse model of high-fat diet-induced obesity
- Optimizing SGLT inhibitor treatment for diabetes with chronic kidney diseases
- Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
- Pharmacological investigations on efficacy of Phlorizin a sodium-glucose co-transporter (SGLT) inhibitor in mouse model of intracerebroventricular streptozotocin …
- Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
- Restoration of the Attenuated Neuroprotective Effect of Ischemic Postconditioning in Diabetic Mice by SGLT inhibitor Phlorizin
- The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE−/− mice
- 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized …
- DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects
- Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2: inhibition kinetics, sidedness of action, and transporter …
- Glycemic effects of SGLT-2 inhibitor Canagliflozin in type 1 diabetes patients using the dexcom G4 platinum CGM
- Consensus Report on Diabetic Ketoacidosis and Adjunctive SGLT inhibitor Therapy in Type 1 Diabetes
- The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with …
- Effects of the SGLT-2 inhibitor empagliflozin on renal tissue oxygenation in non-diabetic subjects: a randomized, double-blind, placebo-controlled study …
- Novel SGLT inhibitor (SGL5094) Improves Postprandial Hyperglycemia Through the Suppression of SGLT1-Mediated Glucose Transport Across the Small Intestine.
- Anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2 (SGLT-2) inhibitor in a normoglycemic rabbit model
- … , tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, in healthy Japanese …
- Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
- Efficient Synthesis of Empagliflozin, an inhibitor of SGLT-2, Utilizing an AlCl3-Promoted Silane Reduction of a β-Glycopyranoside
- Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
- Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats …
- Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers
- Empagliflozin, SGLT 2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of Klotho expression
- Renoprotective effects of combined SGLT 2 and ACE inhibitor therapy in diabetic D ahl S rats
- SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM
- Effects of the sodium‐glucose cotransporter 2 (SGLT 2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats
- Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic …
- Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)
- Efficacy and safety of adding sotagliflozin, a dual sodium‐glucose co‐transporter (SGLT) 1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 …
- … and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor
- Off-target effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitor in cardiovascular disease
- A validated LC‐MS/MS method for the determination of canagliflozin, a sodium–glucose co‐transporter 2 (SGLT‐2) inhibitor, in a lower volume of rat plasma …
- The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical …
- A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK-and HNF1A-MODY than in type 2 diabetes mellitus
- Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
- The sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c changes
- Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: once-weekly semaglutide versus empagliflozin
- Canagliflozin, an SGLT-2 inhibitor, ameliorates acetic acid-induced colitis in rats through targeting glucose metabolism and inhibiting NOX2
- Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis
- A quantitative LC–MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in …
- Effect of a selective SGLT 2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats
- Back off to better blow up: acute GFR decrease at SGLT-2 inhibitor initiation
- SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals …
- Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use
- Liraglutide and dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational …
- SGLT-2 inhibitor intervention in diabetes mellitus patients can reduce the incidence of renal injury and adverse events
- SGLT‐2 inhibitor Renal Outcome Modification in Type‐2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk
- Profile of Ipragliflozin, an Oral SGLT-2 inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
- Fournier’s gangrene under SGLT-2 inhibitor therapy: A literature review and case report
- Synthesis of SGLT-2 inhibitor Empagliflozin
- Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
- 442: Diagnosis and Management of SGLT-2 inhibitor-Induced Euglycemic DKA After Cardiac Surgery
- Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus
- A practical stereoselective synthesis and novel cocrystallizations of an amphiphatic SGLT-2 inhibitor
- The SGLT-2 inhibitor empagliflozin preserves beta cell mass and restores glucose homeostasis in the male diabetic ZDF rat
- US Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 inhibitor Therapy
- Ertugliflozin: a new option in the SGLT-2 inhibitor market for the treatment of type 2 diabetes mellitus
- Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a …
- Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)
- Excess weight loss in a patient with type 2 diabetes mellitus treated with an SGLT-2 inhibitor
- Abstract# 1040609: SGLT-2 inhibitor Prescribing Patterns at Tertiary Care Diabetes Center for Individuals with Diabetes and Heart Failure
- … for cost-savings in the elderly Ontarian population with type 2 diabetes due to reduction in mild hypoglycemia events for SGLT-2 inhibitor versus sulfonylurea (SU) …
- Tubuloglomerular feedback in renal glucosuria: mimicking long-term SGLT-2 inhibitor therapy
- … -1 RECEPTOR AGONIST AND SGLT-2 inhibitor COMBINATION ON BLOOD PRESSURE LEVELS COMPARED TO SGLT-2 inhibitor ALONE: A SYSTEMATIC …
- The SGLT-2 inhibitor dapagliflozin reduces cell death and apoptosis in cardiomyocytes exposed to trastuzumab and doxorubicin through NLRP3-mediated pathways.
- Euglycemic diabetic ketoacidosis precipitated by SGLT-2 inhibitor use, pericarditis, and fasting: a case report
- Euglycemic diabetic ketoacidosis caused by a sodium-glucose co-transporter (SGLT) 2 inhibitor after coronary artery bypass grafting
- P722 Glycemic control with canagliflozin, a SGLT-2 inhibitor, attenuates atherosclerosis and endothelial dysfunction in diabetic apolipoprotein e-deficient mice
- P2295 SGLT 2 inhibitor suppresses atrial fibrillation in the canine model of atrial fibrillation
- … stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor
- Novel SGLT 2 inhibitor: first‐in‐man studies of antisense compound is associated with unexpected renal effects
- Hypomagnesemia-Induced Hypocalcemia Successfully Treated With Sodium-Glucose Cotransport inhibitor (SGLT-2i), a Case Report
- Sodium Glucose Cotransporter-2 (SGLT-2) inhibitor Related Diabetic Ketoacidosis
- About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes
- Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitor drugs: Assessment of safety in Fasting Diabetics
- Abstract# 998903: Euglycemic Relapsing Diabetic Ketaocidosis Due to SGLT-2 inhibitor Use: A Metabolic Challenge in Need of Substrate
- Abstract# 1000873: Euglycemic Relapsing Diabetic Ketaocidosis Due to SGLT-2 inhibitor Use: A Metabolic Challenge in Need of Substrate
- A promising combination for future treatment of type 2 diabetes: Coadministration of empagliflozin (SGLT-2 inhibitor) with linagliptin (DPP-4 inhibitor)
- Evaluation of glycemic control by metformin+ glitazone+ DPP-4 inhibitor+ SGLT-2 inhibitor combination in patients with type 2 diabetes quitting basal/bolus …
- US Prevalence Estimates of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 inhibitor Initiation
- Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus
- Renal outcomes and all-cause death associated with SGLT-2 inhibitor versus other glucose-lowering drugs (CVD-REAL 3 Korea).
- Individualizing treatment with SGLT-2 inhibitor therapy in type 2 diabetes mellitus
- Abstract P233: Sodium Glucose Transporter Type-2 (SGLT-2) inhibitor, Empagliflozin, Improves Cardiovascular Outcomes in Female Diabetic db/db Mice Independent …
- Rare Infection Linked With SGLT-2 inhibitor Use
- Unmasking Type–1 Diabetes Mellitus Following an Episode of Euglycemic Diabetic Ketoacidosis with SGLT-2 inhibitor Use: A Case Report
- A case series of sodium glucose co-transporter-2 inhibitor (SGLT-2i) related diabetic ketoacidosis and literature review of the possible pathophysiology
- Effect of SGLT-2 inhibitor Therapy on Cardiovascular Health in Diabetes Mellitus Patients
- Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes
- SUN-180 Successful Use of SGLT-2 inhibitor Dapagliflozin in Three Patients with Renal Transplant and Diabetes: A Fruit for Thoughts
- SGLT-2 inhibitor-INDUCED DKA: UNMASKING OF LATENT AUTOIMMUNE DIABETES IN ADULTS. CAN WE DO BETTER?
- Use of SGLT‐2 inhibitor in COVID‐19: A cautionary tale
- A Case of Euglycemic DKA With SGLT 2 inhibitor Use-A Diagnostic and Therapeutic Dilemma
- Severe SGLT-2 inhibitor-induced euglycemic ketoacidosis-a rare but serious complication
- 5.1 EFFECTS OF THE SGLT-2 inhibitor EMPAGLIFLOZIN ON VASCULAR FUNCTION AND CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 …
- … agonist; empagliflozin (Jardiance®, Boehringer Ingelheim and Eli Lilly), a SGLT-2 inhibitor; and sitagliptin (Januvia®, Merck), a DPP-4 inhibitor. However, we do …
- BITTER-SWEET DKA: A CASE OF SGLT-2 inhibitor INDUCED EUGLYCEMIC DKA IN A TYPE-1 DIABETIC PATIENT
- SGLT 2 inhibitor induced euglycemic ketoacidosis
- BP reduction with the sodium glucose co-transporter 2 inhibitor (SGLT-2i) empagliflozin (EMPA) in type 2 diabetes (T2D) is similar in treatment naïve as in those on …
- The combinatorial effective approach of alpha-glucosidase inhibitor and Sodium-glucose co-transporter 2 (SGLT-2)
- Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 inhibitor Use and Recent Sleeve Gastrectomy
- First‐dose effect of the SGLT 2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats
- Fournier’s gangrene and diabetic ketoacidosis with lower-than-anticipated glucose levels associated with SGLT-2 inhibitor: A double trouble
- Body weight gain and hyperphagia after administration of SGLT-2 inhibitor: a case report
- Acute interstitial nephritis related to SGLT-2 inhibitor
- … mechanisms underlying the renoprotective effect of empagliflozin, a novel selective sodium glucose co-transporter (SGLT) 2 inhibitor, against diabetic nephropathy in …
- Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C‐MDG
- Euglycemic Diabetic Ketoacidosis in a Patient on a SGLT-2 inhibitor Presenting with Acute Pancreatitis
- Pharmacokinetics, Biotransformation, Distribution and Excretion of Empagliflozin, a Sodium-Glucose Co-Transporter (SGLT 2) inhibitor
- Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes
- Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in type 2 diabetes: a retrospective study
- Euglycemic Diabetic Ketoacidosis With SGLT-2 inhibitor
- Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between …
- Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case …
- SHOULD CARDIOLOGIST PRESCRIBE AN SGLT-2 inhibitor?
- Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in type 2 diabetes
- Acute Renal Failure With Cocaine and SGLT-2 inhibitor
- GLP-1RA as Add-on Therapy to SGLT-2 inhibitor
- Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a …
- Effect of SGLT-2 inhibitor on Bone Turnover in Overweight and Obese Patients with Type 2 Diabetes
- Choosing an SGLT-2 inhibitor for a patient with type 2 diabetes: Which agent (if any) is best
- Effect of tofogliflozin, a SGLT-2 inhibitor, on diabetic ocular complications in SDT rats
- Identification on Anti-Atherosclerotic Mechanism of SGLT-2 inhibitor in Diabetic Rabbit Model
- Upregulation of Toll-Like Receptors That Underlies Diabetes-Induced Exacerbation of Cardiorenal Syndrome is Attenuated by Canagliflozin, an SGLT-2 inhibitor
- Effects of Combination of SGLT-2 inhibitor and GLP-1 Receptor Agonist on Renal Outcome in T2D with GFR below 30 and Macroalbuminuria: A Case Series
- Hyperglycemic Diabetic ketoacidosis precipitated by an SGLT-2 inhibitor in a non-insulin dependant type 2 diabetic
- Effects of SGLT-2 inhibitor on mitochondrial function in renal proximal tubular cell
- SGLT-2 inhibitor: A Unique Antidiabetic in Type 2 Diabetes Mellitus
- Sodium dependent glucose transporter (SGLT) 1/2-elucidating inhibitor SAR and selectivity using homology modelling and 3D QSAR studies.
- Euglycemic DKA after initiating an SGLT-2 inhibitor and the P90X diet
- Effect of dual sodium-glucose cotransporter (SGLT)-1/2 inhibitor sotagliflozin on glycemic and nonglycemic outcomes and on hypoglycemia in type 1 diabetes. A meta …
- Farxiga (Dapagliflozin), an Oral SGLT-2 inhibitor, a New FDA-Approved Treatment Option for Type 2 Diabetes
- Hydrogen-bonded structures and interaction energies in two forms of the SGLT-2 inhibitor sotagliflozin
- Dapagliflozin (forxiga®): SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes
- Ketoacidosis with SGLT-2 inhibitor and Ketogenic Diet: A Case Study
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- SGLT2 inhibitors may predispose to ketoacidosis
- An update on the safety of SGLT2 inhibitors
- SGLT2 inhibitors: are they safe?
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
- Possible adverse effects of SGLT2 inhibitors on bone
- A review on the relationship between SGLT2 inhibitors and cancer
- SGLT2 inhibitors and the diabetic kidney
- Risks associated with SGLT2 inhibitors: an overview
- SGLT2 inhibitors
- An update on SGLT2 inhibitors for the treatment of diabetes mellitus
- SGLT2 inhibitors and mechanisms of hypertension
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- Development of SGLT1 and SGLT2 inhibitors
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
- Effects of SGLT2 inhibitors on cardiovascular outcomes
- Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
- SGLT2 inhibitors: their potential reduction in blood pressure
- SGLT2 inhibitors as a therapeutic option for diabetic nephropathy
- Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
- SGLT2 inhibitors in the treatment of type 2 diabetes
- Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
- SGLT2 inhibitors: the latest “new kids on the block”!
- Cardiac effects of SGLT2 inhibitors: the sodium hypothesis
- SGLT2 inhibitors: molecular design and potential differences in effect
- Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
- SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
- Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors
- SGLT2 inhibitors: benefit/risk balance
- Acute kidney injury from SGLT2 inhibitors: potential mechanisms
- Promise of SGLT2 inhibitors in heart failure: diabetes and beyond
- Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
- Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors
- Metabolism of the failing heart and the impact of SGLT2 inhibitors
- Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans
- Lower risk of death with SGLT2 inhibitors in observational studies: real or bias?
- SGLT2 inhibitors in the management of type 2 diabetes
- Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
- Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans?
- Uric acid and the cardio‐renal effects of SGLT2 inhibitors
- SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms
- The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of …
- SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects
- Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
- SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management
- Synthetic strategies toward SGLT2 inhibitors
- SGLT2 inhibitors and the kidney: effects and mechanisms
- Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
- SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study
- Practical approach to initiating SGLT2 inhibitors in type 2 diabetes
- SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus
- SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
- The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
- Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease
- Are SGLT2 inhibitors ready for prime time for CKD?
- The renal effects of SGLT2 inhibitors and a mini-review of the literature
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and …
- Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
- SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
- Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
- A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
- Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives
- Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
- SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
- Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis
- SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
- SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice
- SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
- Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
- Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure
- The serendipitous story of SGLT2 inhibitors in heart failure: new insights from DECLARE-TIMI 58
- Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
- SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission
- Mechanisms in endocrinology: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?
- SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
- SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
- Does lower limb amputation concern all SGLT2 inhibitors?
- SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
- Adverse effects of SGLT2 inhibitors on bone health
- Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors
- Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications
- Acute kidney injury and adverse renal events in patients receiving SGLT2–inhibitors: a systematic review and meta-analysis
- SGLT2 inhibitors: cardiovascular benefits beyond HbA1c—translating evidence into practice
- SGLT2 inhibitors: nephroprotective efficacy and side effects
- SGLT2 inhibitors: β blockers for the kidney?
- Adoption of new glucose-lowering medications in the US—the case of SGLT2 inhibitors: nationwide cohort study
- Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with …
- SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta‐analysis
- Use of SGLT2 inhibitors for diabetes and risk of infection: analysis using general practice records from the NPS MedicineWise MedicineInsight program
- Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind …
- SGLT2 inhibitors in T2D and associated comorbidities—differentiating within the class
- Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data
- SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in type 2 diabetes mellitus
- SGLT2 inhibitors: glucuretic treatment for type 2 diabetes
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney …
- The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis
- SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
- Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review
- Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
- Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
- SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
- SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis
- Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using …
- Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low‐grade inflammation the neglected component?
- SGLT2 inhibitors and urinary tract infections
- Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
- Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
- Safety of SGLT2 inhibitors in patients with diabetes mellitus
- Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale …
- SGLT2 inhibitors through the windows of EMPA-REG and CANVAS trials: a review
- Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care
- Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta‐analysis
- Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus
- SGLT2 inhibitors and diabetic ketoacidosis—a growing concern
- Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta‐analysis
- The role of kidney in glucose homeostasis–SGLT2 inhibitors, a new approach in diabetes treatment
- SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes
- SGLT2 inhibitors–an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
- The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
- Risk of amputations associated with SGLT2 inhibitors compared to DPP‐4 inhibitors: a propensity‐matched cohort study
- SGLT2 inhibitors and cardiovascular outcomes: current perspectives and future potentials
- SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes
- The role of the kidney and SGLT2 inhibitors in type 2 diabetes
- Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center
- Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?
- Renoprotective effects of GLP1R agonists and SGLT2 inhibitors
- SGLT2 inhibitors: practical considerations and recommendations for cardiologists
- Discovery of non-glucoside SGLT2 inhibitors
- Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm
- Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities
- Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and …
- SGLT2 inhibitors‘ interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn
- Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes
- Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
- Clinical implication of SGLT2 inhibitors in type 2 diabetes
- Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus
- ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease
- SGLT2–inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2–inhibitors in clinical practice
- SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem
- SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
- Mechanisms of protective effects of SGLT2 inhibitors in cardiovascular disease and renal dysfunction
- SGLT2 inhibitors for diabetes: turning symptoms into therapy.
- Effects of SGLT2 inhibitors on circulating stem and progenitor cells in patients with type 2 diabetes
- Design of SGLT2 inhibitors for the treatment of type 2 diabetes: a history driven by biology to chemistry
- The expanding résumé of SGLT2 inhibitors
- Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure
- Renoprotective effects of SGLT2 inhibitors: beyond glucose reabsorption inhibition
- Benefits of SGLT2 inhibitors beyond glycemic control–a focus on metabolic, cardiovascular and renal outcomes
- Update on SGLT2 inhibitors—new data released at the American Diabetes Association
- Generalizability of cardiovascular safety trials on SGLT2 inhibitors to the real world: implications for clinical practice
- Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
- Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization
- Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes
- Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
- Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1, 3, 4-thiadiazolylmethylphenyl glucoside congeners
- SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes
- SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
- Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia
- Efficacy and safety of SGLT2 inhibitors in patients with type 1 diabetes: a meta-analysis of randomized controlled trials
- The role of SGLT2 inhibitors in managing type 2 diabetes
- SGLT2 inhibitors and cancer: why further evidence is required
- Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology
- Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
- Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors
- Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media
- SGLT2 inhibitors and risk of genitourinary infections
- The effect of SGLT2 inhibitors on cardiovascular events and renal function
- SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
- The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties
- Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?
- Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus
- SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
- Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data
- Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: symbiotic effects on metabolism and cardiorenal risk
- Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors
- Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: an …
- How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology
- A new HPLC–MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy …
- … -gl
